Diagnostic and treatment of familial hypercholesterolemia (FH) in adult: Guidelines from the New French Society of Atherosclerosis (NSFA);Diagnostic et traitement des hypercholestérolémies familiales (HF) chez l'adulte: Recommandations de la Nouvelle société française d'athérosclérose (NSFA)

Presse Medicale

Volumn 42, Issue 6 PART1, 2013, Pages 930-950

  Farnier, Michel ^a   Bruckert, Eric ^b   Boileau, Catherine ^c   Krempf, Michel ^d  

^a Point Medical   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

^d CHU de Nantes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; DNA; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

APO B100 GENE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DNA SCREENING; DRUG EFFICACY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE; GENE MUTATION; HUMAN; PCSK9 GENE; PRACTICE GUIDELINE; RISK ASSESSMENT; SECONDARY PREVENTION; SEX DIFFERENCE; TREATMENT RESPONSE;

EID: 84879148621     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2013.01.053     Document Type: Article

References (121)

1. Afssaps. Prise en charge thérapeutique du patient dyslipidémique. Recommandations mars 2005. http://www.agmed.sante.gouv.fr/.
2. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Educations Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
3. ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2011, 32:1769-1818. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
4. Luc G., Girardet J.-P., Bruckert E., Rieu D., Farnier M., Darmaun D. Recommandations pour la prise en charge des hypercholestérolémies chez l'enfant. STV 2010, 22:465-477.
5. Varret M., Abifadel M., Rabès J.P., Boileau C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin Genet 2008, 73:1-13.
6. Marks D., Thorogood M., Neil H.A., Humphries S.E. A review on the diagnosis, natural history, and treatment of familial hypercholesterolemia. Atherosclerosis 2003, 168:1-14.
7. Wierzbicki A.S., Humphries S.E., Minhas R. Familial hypercholesterolemia: summary of NICE guidance. BMJ 2008, 337:a1095.
8. Alonso R., Mata N., Castillo S., Fuentes F., Saenz P., Muniz O., et al. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 2008, 200:315-321.
9. Ferrieres J., Lambert J., Lussier-Cacan S., Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 1995, 92:290-295.
10. Jansen A.C.M., van Aalst-Cohen E.S., Tanck M.W., Trip M.D., Lansberg P.J., Liem A.H., et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400patients. J Intern Med 2004, 256:482-490.
11. Neil H.A.W., Seagroatt V., Betteridge D.J., Cooper M.P., Durrington P.N., Miller J.P., et al. Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart 2004, 90:1431-1437.
12. Humphries S.E., Whittall R.A., Hubbart C.S., Maplebeck S., Cooper J.A., Soutar A.K., et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Gen 2006, 43:943-949.
13. Austin M.A., Hutter C.M., Zimmern R.L., Humphries S.E. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 2004, 160:421-429.
14. Robinson J.G., Stone N.J. Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am J Cardiol 2006, 98:1405-1408.
15. Marma A.K., Lloyd-Jones D.M. Systematic examination of the updated Framingham heart study general cardiovascular risk profile. Circulation 2009, 120:384-390.
16. Robinson J.G., Goldberg A.C. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011, 5(Suppl):S18-S29.
17. Nordestgaard B.G., Chapman M.J., Ray K., Borén J., Andreotti F., Watts GFet al. Lipoprotein (a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31:2844-2853.
18. Nenseter M.S., Lindvig H.W., Ueland T., Langslet G., Ose L., Holven K.B., et al. Lipoprotein (a) levels in coronary heart disease-susceptible and-resistant patients with familial hypercholesterolemia. Atherosclerosis 2011, 216:426-432.
19. Marduel M., Carrié A., Sassolas A., Devillers M., Carreau V., Di Filippo M., et al. Molecular spectrum of autosomal dominant hypercholesterolemia in France. Hum Mutat 2010, 31:E1811-E1824.
20. Hobbs H.H., Russell D.W., Brown M.S., Goldstein J.L. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 1990, 24:133-170.
21. Hobbs H.H., Brown M.S., Goldstein J.L. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992, 1:445-466.
22. Abifadel M., Varret M., Rabes J.P., Allard D., Ouguerram J., Devillers M., et al. Mutations in PCSK9cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
23. Beeharry D., Coupe B., Benbow E.W., Morgan J., Kwok S., Charlton-Menys V., et al. Familial hypercholesterolaemia commonly presents with Achilles tenosynovitis. Ann Rheum Dis 2006, 65:312-315.
24. Christoffersen M., Frikke-Schmidt R., Schnohr P., Jensen G.B., Norderstgaard B.G., Tybjaerg-Hansen A. Xanthelasmata, arcus corneae, and ischaemic vascular disease and death in general population: prospective cohort study. BMJ 2011, 343:d5497. [on line].
25. Starr B., Hadfield S.G., Hutten B.A., Lansberg P.J., Leren T.P., Damgaard D., et al. Development of sensitive and specific age- and gender-specific low density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med 2008, 46:791-803.
26. van Aalst-Cohen E.S., Jansen A.C., de Jongh S., de Sauvage Nolting P.R., Kastelein J.J. Clinical, diagnostic, and therapeutic aspects of familial hypercholesterolemia. Semin Vasc Med 2004, 4:31-41.
27. Identification and management of familial hypercholesterolemia. NICE 2008. http://www.nice.org.uk/.
28. Nouvelle Société française d'athérosclérose. www.nsfa.asso.fr.
29. Taylor A., Wang D., Patel K., Whittal R., Wood G., Farrer M., et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet 2010, 77:572-580.
30. Herman K., Van Heyningen C., Wile D. Cascade screening for familial hypercholesterolaemia and its effectiveness in the prevention of vascular disease. Br J Diabet Vasc Dis 2009, 9:171-174.
31. Watts G.F., Lewis B., Sullivan D.R. Familial hypercholesterolemia: a missed opportunity in preventive medicine. Nat Clin Pract Cardiovasc Med 2007, 4:404-405.
32. Defesche J.C., Lansberg P.J., Umans-Eckenhausen M.A., Kastelein J.J. Advanced method for the identification of patients with inherited hypercholesterolemia. Semin Vasc Med 2004, 4:59-65.
33. Marang-van de Mheen P.J., ten Asbroek A.H., Bonneux L., Bonsel G.J., Klazinga N.S. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolemia in The Netherlands. Eur Heart J 2002, 23:1922-1930.
34. Wonderling D., Umans-Eckenhausen M.A., Marks D., Defesche J.C., Kastelein J.J., Thorogood M. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in the Netherlands. Semin Vasc Med 2004, 4:97-104.
35. Umans-Eckenhausen M.A., Defesche J.C., Sijbrands E.J., Scheerder R.L., Kastelein J.J. Review of first 5years of screening for familial hypercholesterolemia in the Netherlands. Lancet 2001, 357:165-168.
36. Humphries S.E., Neil H.A.W. Developing and applying clinically useful approaches to identify individuals with familial hypercholesterolemia in the UK. Clin Lipidol 2010, 5:497-507.
37. Gray J., Jaiyeola A., Whiting M., Modell M., Wierzbicki A.S. Identifying patients with familial hypercholesterolemia in primary care: an informatics-based approach in one primary care centre. Heart 2008, 94:754-758.
38. Minhas R., Humphries S.E., Qureshi N., Neil H.A.W. Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. Heart 2009, 95:584-587. on behalf of the NICE Guideline Development Group.
39. Alonso R., Mata P., De Andres R., Villascatin P.B., Martinez-Gonzalez J., Badimon L. Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. Atherosclerosis 2001, 157:423-429.
40. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regiments. JAMA 1990, 264:3007-3012.
41. Kroon A.A., Aengevaeren W.R., Van der W.T., Uijen G.J., Reiber J.H., Brushke A.V. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996, 93:1826-1835.
42. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J., Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001, 357:577-581.
43. Versmissen J., Oosterveer D.M., Yazdanpanah M., Defesche J.C., Basart D.C., Liem A.H. Efficacy of statins in familial hypercholesterolaemia: a long-term cohort study. BMJ 2008, 337:a2423. [on line].
44. Neil A., Cooper J., Betteridge J., Capps N., McDowell I., Durrington P. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008, 29:2625-2633.
45. Scandinavian Simvastatin Survival Study G Randomised trial of cholesterol lowering in 4444patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
46. Shepherd J., Cobbe S., Ford I., Isles C.G., Lorimer A.G., MacFarlane P.W. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307.
47. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056participants in 14randomised trials of statins. Lancet 2005, 366:1267-1278. Cholesterol Treatment Trialists' (CTT) Collaborators.
48. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000participants in 26randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists' (CTT) Collaboration.
49. Robinson J.G., Smith B., Maheshwari N., Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005, 46:1855-1862.
50. Dorr A., Gundersen K., Schneider J., Spencer T., Martin W. Colestipol hydrochloride in hypercholesterolemic patients-effect on serum cholesterol and mortality. J Chron Dis 1978, 31:5-14.
51. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984, 251:351-364. Lipid Research Clinics.
52. Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-380. Coronary Drug Project.
53. Robinson J.G., Wand S., Smith B.J., Jacobson T.A. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009, 53:316-322.
54. Buchwald H., Varco R., Matts J., Long J.M., Fitch L.L., Campbell G.S., et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control on the Hyperlipidemias (POSCH). N Engl J Med 1990, 323:946-955.
55. van Wissen S., Smilde T.J., Trip M.D., Stalenhoef A.F.H., Kastelein J.J.P. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol 2005, 95:264-266.
56. Kastelein J.J.P., Akdim F., Stroes E.S.G., Zwinderman A.H., Bots M.L., Stalenhoef A.F. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443.
57. Robinson J.G., Davidson M. Is it over for ezetimibe?. Exp Rev Cardiovasc Ther 2008, 6:781-783.
58. Sivalaratnam S., van Loendersloot L.L., Hutten B.A., Kastelein J.J.P., Trip M.D., de Groot E. Long-term LDL-C lowering in heterozygous familial hypercholesterolemia normalizes carotid intima-media thickness. Atherosclerosis 2010, 212:571-574.
59. http://www.acc.org%20ou%20www.americanheart.org/.
60. Bots M.L., Baldassarre D., Simon A., de Groot E., O'Leary D.H., Riley W., et al. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations?. Eur Heart J 2007, 28:398-406.
61. Awan Z., Alrasadi K., Francis G.A., Hegele R.A., McPherson R., Frohlich J., et al. Vascular calcifications in homozygote familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2008, 28:777-785.
62. Kolansky D.M., Cuchel M., Clark B.J., Paridon S., McCrindle B.W., Wiegers S.E., et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008, 102:1438-1443.
63. Neefjes L.A., Ten Kate G.J., Rossi A., Galema-Boers A.J., Langendonk J.G., Weustink A.C., et al. CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia. Heart 2011, 97:1151-1157.
64. Miname M.H., Ribeiro M.S., Parga Filho J., Avila L.F., Bortolotto L.A., Martinez L.R., et al. Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia. Atherosclerosis 2010, 213:486-491.
65. Alrasadi K., Alwaili K., Awan Z., Valenti D., Couture P., Genest J. Aortic calcifications in familial hypercholesterolemia: potential role of the low-density lipoprotein receptor gene. Am Heart J 2009, 157:170-176.
66. Lichtenstein A.H., Ausman L.M., Jalbert S.M., Vilella-Bach M., Jauhiainen M., Mc Gladdery S., et al. Efficacy of therapeutic lifestyle change/step2diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects. J Lipid Res 2002, 43:264-273.
67. Bruckert E., Rosenbaum D. Lowering LDL cholesterol through diet: potential role in the statin era. Curr Opin Lipidol 2011, 22:43-48.
68. Brown L., Roener B., Willett W.W., Sacks F.M. Cholesterol lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999, 69:30-42.
69. Demonty I., Ras R.T., van der Knaap H.C.M., Duchateau G.S., Meijer L., Zock P.L., et al. Continuous dose-response relationship of the LDL cholesterol-lowering effect of phytosterol intake. J Nutr 2009, 139:271-284.
70. Dattilo A.M., Kris-Etherton P.M. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992, 56:320-328.
71. Connor W.E., Connor S.L. Dietary treatment of familial hypercholesterolemia. Arteriosclerosis 1989, 9(Suppl.1):I91-I105.
72. Castro Cabezas M., de Vries J.H., Van Oostrom A.J., Iestra J., van Staveren W.A. Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins. J Am Diet Assoc 2006, 106:1564-1569.
73. Goldberg A.C., Ostlund R.E., Bateman J.H., Schimmoeller L., Mc Pherson T.B., Spilburg C.A. Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. Am J Cardiol 2006, 97:376-379.
74. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004, 173:55-68.
75. Ito M.K., McGowan M.P., Moriarty P.M. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011, 5(Suppl. 3):S38-S45.
76. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES Study). Am J Cardiol 1998, 81:582-587.
77. Jones P.H., Davidson M.H., Stein E.A. Comparison of the efficacy and safety of rosuvvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003, 92:152-160.
78. Stein E.A., Amerena J., Ballantyne C.M., Brice E., Farnier M., Guthrie R.M., et al. Long-term efficacy and safety of rosuvastatin 40mg in patients with severe hypercholesterolemia. Am J Cardiol 2007, 100:1387-1396.
79. Armitage J. The safety of statins in clinical practice. Lancet 2007, 370:1781-1790.
80. Mc Kenney J.M., Davidson M.H., Jacobson T.A., Guyton J.R. Final conclusions and recommendations oft he National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006, 97:C89-C94. National Lipid Association Statin Safety Task Force Liver Expert Panel.
81. Ge L., Wang J., Qi W., Miao H.H., Cao J., Qu X.Y., et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab 2008, 7:508-519.
82. Pandor A., Ara R.M., Tumur I., Wilkinson A.J., Paisley S., Duenas A., et al. Ezetimibe monotherapy for cholesterol lowering in 2722people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009, 265:568-580.
83. Birjmohun R.S., Hutten B.A., Kastelein J.J., Stroes E.S.G. Efficacy and safety of high-density lipoprotein cholesterol-increasing coumpounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005, 45:185-197.
84. Huijgen R., Kindt I., Verhoeven S.B.J., Sijbrands E.J., Vissers M.N., Kastelein J.J., et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. Plos One 2010, 5:e9220. [on line].
85. Pijlman A.H., Huijgen R., Verhagen S.N., Imholz B.P., Liem A.H., Kastelein J.J., et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010, 209:189-194.
86. Stein E., Stender S., Mata P., Sager P., Ponsonnet D., Melani L., et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004, 148:447-455.
87. Hamilton-Craig I., Kostner K., Colquhoun D., Woodhouse S. Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vasc Health Risk Manag 2010, 6:1023-1037.
88. Huijgen R., Abbink E.J., Bruckert E., Stalenhoef A.F., Imholz B.P., Durrington B.P., et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomised, double-blind, controlled trial. Clin Ther 2010, 32:615-625.
89. Thompson G.R. Recommendations for the use of LDL apheresis. Atherosclerosis 2008, 198:247-255. HEART-UK LDL Apheresis Working Group.
90. Thompson G.R., Catapano A., Saheb S., Atassi-Dumont M., Barbir M., Eriksson M. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol 2010, 21:492-498.
91. Thompson G.R., Barbir M., Davies D., Dobral P., Gesinde M., Livingstone M., et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010, 208:317-321.
92. Thompson G.R. LDL apheresis. Atherosclerosis 2003, 167:1-13.
93. Marais A.D., Naoumova R.P., Firth J.C., Penny C., Neuwirth C.K., Thompson G.R. Decreased production of low-density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res 1997, 38:2071-2078.
94. Pfohl M., Naoumova R.P., Klass C., Knisel W., Jakober B., Risler T. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-Co. A reductase inhibitor therapy. J Lipid Res 1994, 35:1946-1955.
95. Thompsen J., Thompson P.D. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 2006, 189:31-38.
96. Tatami R., Inove N., Itoh H., Kishino B., Koga N., Nakashima Y., et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesrolemia: a multicenter study. The LARS Investigators. Atherosclerosis 1992, 95:1-13.
97. Waidner T., Franzen D., Voelker W., Ritter M., Borberg H., Hombach V., et al. The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study. Clin Investig 1994, 72:858-863.
98. Schuff-Werner P., Gohike H., Bartmann U., Baggio G., Corti M.C., Dinsenbacher A., et al. The HELP-LDL-apheresis multicenter study, an angiographically assesses trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease II. Final evaluation of the effect of regular treatment on LDL cholesterol plasma concentration and the course of coronary heart disease. Eur J Clin Invest 1994, 24:724-732.
99. Thompson G.R., Maher V.M., Matthews, Kitano Y., Neuwirth C., Shortt M.B., et al. Familial hypercholesterolemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995, 345:811-816.
100. Kroon A.A., Aengevaeren W.R., van den Werf T., Uijen G.J., Reiber J.H., Bruschke A.V., et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment of coronary atherosclerosis. Circulation 1996, 93:1826-1835.
101. Mabuchi H., Koizumi J., Shimizu M., Kajinami K., Miyamoto S., Ueda K., et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998, 82:1489-1495.
102. Ritcher W.O., Donner M.G., Hofling B., Schwandt P. Long-term of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism 1998, 47:863-868.
103. Tamai O., Matsuoka H., Itabe Y., Kohno K., Imaisumi T. Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemia humans. Circulation 1997, 95:76-82.
104. Igarashi K., Tsuji M., Nishimura M., Horimoto M. Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia. J Clin Apher 2004, 19:11-16.
105. Sato M., Amano I. Changes in oxidative stress and microcirculation by low-density lipoprotein apheresis. Ther Apher Dial 2003, 7:419-424.
106. Kobayashi K., Yamashita K., Tasaki H., Suzuka H., Nihei S., Ozumi K., et al. Evaluation of improtved coronary flow velocity reserve using transthoracic Doppler echocardiography after single LDL apheresis. Ther Apher Dial 2004, 8:383-389.
107. Choh S.A., Choh N.A., Rasool A., Yousuf R., Qureshi U. Homozygous familial hypercholesterolemia. J Pediatr Endocrinol Metab 2009, 22:573-575.
108. Morrisett J.D., Vickers K.C. Vascular calcification in homozygote familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2008, 28:606-607.
109. Naoumova R.P., Thompson G.R., Soutar A.K. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol 2004, 15:413-422.
110. Goldammer A., Wiltschnig S., Heinz G., Jansen M., Stulnig T., Hört W.H., et al. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia. Metabolism 2002, 51:976-980.
111. Raal F.J., Pilcher G.J., Panz V.R., van Deventer H.E., Brice B.C., Blom D.J., et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011, 124:2202-2207.
112. Gagné C., Gaudet D., Bruckert E. Efficacy and safety of ezetimibe co-administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105:2469-2475. Ezetimibe Study Group.
113. Hudgins L.C., Kleinman B., Scheuer A., White S., Gordon B.R. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol 2008, 102:1199-1204.
114. Raal F.J., Santos R.D., Blom D.J., Marais A.D., Charng M.J., Cromwell W.C., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:998-1006.
115. Rizzo M. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. IDrugs 2010, 13:103-111.
116. Thorogood M., Seed M., De Mott K. Management of fertility in women with familial hypercholesterolemia summary of a NICE guidance. BJOG 2009, 116:478-479.
117. Loke D.F., Viegas O.A., Kek L.P., Rauff M., Thai A.C., Ratmam S.S. Lipid profils during and after normal pregnancy. Gynecol Obstet Invest 1991, 32:144-147.
118. Martin U., Davies C., Hayavi S., Hartland A., Dunne F. Is normal pregnancy atherogenic?. Clin Sci (Lond) 1999, 96:421-425.
119. Amundsen A.L., Khoury J., Iversen P.O., Bergei C., Ose L., Tonstad S. Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis 2006, 189:451-457.
120. Kusters D.M., Homsma S.J.M., Hutten M.T.B., Twickler M.T., Avis H.J., van der Post J.A., et al. Dilemmas in treatment of women with familial hypercholesterolemia during pregnancy. Neth J Med 2010, 68:299-303.
121. Klingel R., Gohlen B., Schwarting A., Himmelsbach F., Straube R. Differential indication of lipoprotein apheresis during pregnancy. Ther Apher Dial 2003, 7:359-364.